These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

270 related articles for article (PubMed ID: 22898344)

  • 21. Is there tachyphylaxis to intravitreal anti-vascular endothelial growth factor pharmacotherapy in age-related macular degeneration?
    Schaal S; Kaplan HJ; Tezel TH
    Ophthalmology; 2008 Dec; 115(12):2199-205. PubMed ID: 18930553
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Pharmacogenetics for genes associated with age-related macular degeneration in the Comparison of AMD Treatments Trials (CATT).
    Hagstrom SA; Ying GS; Pauer GJT; Sturgill-Short GM; Huang J; Callanan DG; Kim IK; Klein ML; Maguire MG; Martin DF;
    Ophthalmology; 2013 Mar; 120(3):593-599. PubMed ID: 23337555
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The safety of bevacizumab and ranibizumab in clinical studies.
    De Rosa M; Messori A
    Int Ophthalmol; 2015 Apr; 35(2):157-8. PubMed ID: 25646753
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Ranibizumab versus Bevacizumab for Neovascular Age-related Macular Degeneration: Results from the GEFAL Noninferiority Randomized Trial.
    Kodjikian L; Souied EH; Mimoun G; Mauget-Faÿsse M; Behar-Cohen F; Decullier E; Huot L; Aulagner G;
    Ophthalmology; 2013 Nov; 120(11):2300-9. PubMed ID: 23916488
    [TBL] [Abstract][Full Text] [Related]  

  • 25. VEGFR2 Gene Polymorphisms and Response to Anti-Vascular Endothelial Growth Factor Therapy in Age-Related Macular Degeneration.
    Hagstrom SA; Ying GS; Maguire MG; Martin DF; ; Gibson J; Lotery A; Chakravarthy U;
    Ophthalmology; 2015 Aug; 122(8):1563-8. PubMed ID: 26028346
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Intravitreal bevacizumab for previously treated choroidal neovascularization from age-related macular degeneration.
    Goff MJ; Johnson RN; McDonald HR; Ai E; Jumper JM; Fu A
    Retina; 2007; 27(4):432-8. PubMed ID: 17420694
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Anti-vascular endothelial growth factor for neovascular age-related macular degeneration: a meta-analysis of randomized controlled trials.
    Nguyen CL; Oh LJ; Wong E; Wei J; Chilov M
    BMC Ophthalmol; 2018 May; 18(1):130. PubMed ID: 29843663
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Bevacizumab for choroidal neovascularization secondary to age-related macular degeneration and pathological myopia.
    Hashemi S; Faramarzi MA; Ghasemi Falavarjani K; Abdollahi M
    Expert Opin Biol Ther; 2014 Dec; 14(12):1837-48. PubMed ID: 25283631
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cytokines in neovascular age-related macular degeneration: fundamentals of targeted combination therapy.
    de Oliveira Dias JR; Rodrigues EB; Maia M; Magalhães O; Penha FM; Farah ME
    Br J Ophthalmol; 2011 Dec; 95(12):1631-7. PubMed ID: 21546514
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Antivascular endothelial growth factor agents and their development: therapeutic implications in ocular diseases.
    Kaiser PK
    Am J Ophthalmol; 2006 Oct; 142(4):660-8. PubMed ID: 17011860
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Ranibizumab for the treatment of neovascular age-related macular degeneration: a review.
    Kourlas H; Abrams P
    Clin Ther; 2007 Sep; 29(9):1850-61. PubMed ID: 18035187
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Safety implications of vascular endothelial growth factor blockade for subjects receiving intravitreal anti-vascular endothelial growth factor therapies.
    Csaky K; Do DV
    Am J Ophthalmol; 2009 Nov; 148(5):647-56. PubMed ID: 19712924
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Ocular and systemic safety of bevacizumab and ranibizumab in patients with neovascular age-related macular degeneration.
    Johnson D; Sharma S
    Curr Opin Ophthalmol; 2013 May; 24(3):205-12. PubMed ID: 23518613
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Safety of ranibizumab in routine clinical practice: 1-year retrospective pooled analysis of four European neovascular AMD registries within the LUMINOUS programme.
    Holz FG; Bandello F; Gillies M; Mitchell P; Osborne A; Sheidow T; Souied E; Figueroa MS;
    Br J Ophthalmol; 2013 Sep; 97(9):1161-7. PubMed ID: 23850682
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Intravitreal bevacizumab (Avastin) vs. ranibizumab (Lucentis) for the treatment of age-related macular degeneration: a systematic review.
    Schmucker C; Ehlken C; Hansen LL; Antes G; Agostini HT; Lelgemann M
    Curr Opin Ophthalmol; 2010 May; 21(3):218-26. PubMed ID: 20393293
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A systematic review of the adverse events of intravitreal anti-vascular endothelial growth factor injections.
    van der Reis MI; La Heij EC; De Jong-Hesse Y; Ringens PJ; Hendrikse F; Schouten JS
    Retina; 2011 Sep; 31(8):1449-69. PubMed ID: 21817960
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Anti-vascular endothelial growth factor pharmacotherapy for age-related macular degeneration: a report by the American Academy of Ophthalmology.
    Ip MS; Scott IU; Brown GC; Brown MM; Ho AC; Huang SS; Recchia FM;
    Ophthalmology; 2008 Oct; 115(10):1837-46. PubMed ID: 18929163
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Submacular haemorrhage after intravitreal bevacizumab compared with intravitreal ranibizumab in large occult choroidal neovascularization.
    Krishnan R; Goverdhan S; Lochhead J
    Clin Exp Ophthalmol; 2009 May; 37(4):384-8. PubMed ID: 19594565
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Characteristics of Eyes With Good Visual Acuity at 5 Years After Initiation of Treatment for Age-Related Macular Degeneration but Not Receiving Treatment From Years 3 to 5: Post Hoc Analysis of the CATT Randomized Clinical Trial.
    Scoles D; Ying GS; Pan W; Hua P; Grunwald JE; Daniel E; Jaffe GJ; Toth CA; Martin DF; Maguire MG;
    JAMA Ophthalmol; 2020 Mar; 138(3):276-284. PubMed ID: 31999297
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Comparison of ranibizumab and bevacizumab for neovascular age-related macular degeneration according to LUCAS treat-and-extend protocol.
    Berg K; Pedersen TR; Sandvik L; Bragadóttir R
    Ophthalmology; 2015 Jan; 122(1):146-52. PubMed ID: 25227499
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.